IL209798A0 - Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+ t cells - Google Patents

Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+ t cells

Info

Publication number
IL209798A0
IL209798A0 IL209798A IL20979810A IL209798A0 IL 209798 A0 IL209798 A0 IL 209798A0 IL 209798 A IL209798 A IL 209798A IL 20979810 A IL20979810 A IL 20979810A IL 209798 A0 IL209798 A0 IL 209798A0
Authority
IL
Israel
Prior art keywords
regulatory
cells
lead
generation
antibodies block
Prior art date
Application number
IL209798A
Other languages
English (en)
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of IL209798A0 publication Critical patent/IL209798A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL209798A 2008-06-06 2010-12-06 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+ t cells IL209798A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5964708P 2008-06-06 2008-06-06
PCT/US2009/046464 WO2009149382A2 (en) 2008-06-06 2009-06-05 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells

Publications (1)

Publication Number Publication Date
IL209798A0 true IL209798A0 (en) 2011-02-28

Family

ID=41398905

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209798A IL209798A0 (en) 2008-06-06 2010-12-06 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+ t cells

Country Status (14)

Country Link
US (1) US20090304659A1 (enExample)
EP (1) EP2297204A4 (enExample)
JP (1) JP2011522835A (enExample)
KR (1) KR20110025812A (enExample)
CN (1) CN102112491A (enExample)
AU (1) AU2009255999A1 (enExample)
BR (1) BRPI0915582A2 (enExample)
CA (1) CA2728772A1 (enExample)
IL (1) IL209798A0 (enExample)
MX (1) MX2010013265A (enExample)
NZ (1) NZ590197A (enExample)
TW (1) TW201000130A (enExample)
WO (1) WO2009149382A2 (enExample)
ZA (1) ZA201100061B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Ｃｄ５６陽性ｔ細胞増強方法
US10092597B2 (en) 2014-01-14 2018-10-09 The University Of Hong Kong Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
WO2018085897A1 (en) * 2016-11-14 2018-05-17 Murdoch Childrens Research Institute Transplant rejection assay
KR102880156B1 (ko) * 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
US20220227887A1 (en) 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
US20240209089A1 (en) * 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法
EP4340866A4 (en) 2021-05-19 2025-05-21 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
CA1339840C (en) * 1988-12-16 1998-04-28 Kenneth Kortright Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
CA2096530A1 (en) * 1990-11-23 1992-05-24 Thomas Russell Method and apparatus for screening microscopic cells utilizing light scatter techniques
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US6335174B1 (en) * 1996-04-05 2002-01-01 South Alabama Medical Science Foundation Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US6803036B1 (en) * 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
JP4344696B2 (ja) * 2002-09-27 2009-10-14 バイオイー， インコーポレイテッド 細胞分離組成物および細胞分離法
CA2522380A1 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Specific inhibition of allorejection
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2008005859A2 (en) * 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells

Also Published As

Publication number Publication date
MX2010013265A (es) 2011-02-24
CN102112491A (zh) 2011-06-29
JP2011522835A (ja) 2011-08-04
WO2009149382A3 (en) 2010-04-29
NZ590197A (en) 2012-10-26
TW201000130A (en) 2010-01-01
AU2009255999A1 (en) 2009-12-10
BRPI0915582A2 (pt) 2016-01-26
EP2297204A4 (en) 2013-10-23
CA2728772A1 (en) 2009-12-10
US20090304659A1 (en) 2009-12-10
EP2297204A2 (en) 2011-03-23
KR20110025812A (ko) 2011-03-11
WO2009149382A2 (en) 2009-12-10
ZA201100061B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
ZA201100061B (en) Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
EP2416652A4 (en) METHODS OF ADMINISTERING OLIGONUCLEOTIDES INTO DIRECTION OF IMMUNE CELLS
ZA201301013B (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
ZA201208525B (en) Antibodies to human gdf8
WO2012082841A9 (en) Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
ZA201205529B (en) Methods and uses relating to fuel compositions
ZA201104349B (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
ZA201202300B (en) Preparation of solar modules
GB0901605D0 (en) Back contacting and interconnection of two solar cells
PL3210991T3 (pl) Postać krystaliczna lewoizowalerylospiramycyny II oraz preparaty, sposoby wytwarzania i ich zastosowanie
IL216842A (en) Methods for producing hybrid / chimeric cells and their uses
AP3739A (en) Conversion of natural gas
IL216751A0 (en) Methods of generating cells exhibiting phenotypic plasticity
ZA201302750B (en) Method of generating thermal energy
GB201006268D0 (en) Improvements in or relating to gas turbine engines
TWM401255U (en) Connector structure for solar energy
AU2009902649A0 (en) Methods of generating cells exhibiting phenotypic plasticity
PL391892A1 (pl) Sposób przygotowania i spalania biomasy organicznej w kotle energetycznym
GB201008457D0 (en) Energy system relating to the forces of gravity and buoyancy
GB0916130D0 (en) Solar powered gas turbine with direct input of solar radiation to the turbine
IL226040A0 (en) Methods for generating antibodies to metalloenzymes
GB201017731D0 (en) Solar powered rocket
AU2009902652A0 (en) Methods of generating hybrid/chimeric cells, and uses thereof
GB201021613D0 (en) Method of explosive bonding which facilitates the use of interlayer materials which are otherwise too expensive to incorporate as an interlayer
PL398442A1 (pl) Kasety ekspresyjne, cząsteczki T-DNA, roślinne wektory ekspresyjne, transgeniczne komórki roślinne oraz ich zastosowanie do wytwarzania szczepionki